|
|
Vaccine Detail
|
MT-201-GBM monocyte vaccine |
| Vaccine Information |
- Vaccine Name: MT-201-GBM monocyte vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: pp65CMV antigen (NCT04741984; NCIT_C179670)
- Immunization Route: Intravenous injection (i.v.)
- Description: This is a cancer cell vaccine consisting of autologous monocytes loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the lysosome-associated membrane protein (LAMP), with potential immunostimulatory and antineoplastic activities. The autologous CMV-pp65-LAMP mRNA loaded monocyte vaccine MT-201-GBM exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of LAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. (NCIT_C179670) MT-201-GBM (pp65CMV antigen monocytes) are administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O[6]-methylguanine-DNA methyltransferase) (MGMT) gene promoter. The vaccine is made from a type of immune cell called monocytes, which have been engineered to express a cytomegalovirus (CMV) protein. Patients also receive standard radiation therapy combined with temozolomide. (NCT04741984)
|
| Host Response |
|
|
| References |
NCIT_C179670: Autologous CMV-pp65-LAMP mRNA Loaded Monocyte Vaccine MT-201-GBM [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C179670]
NCT04741984: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM (DEMAND) [https://clinicaltrials.gov/study/NCT04741984]
|
|
